ACTA ENDOCRINOLOGICA (BUC)

Objectives. The objective of this retrospective study was to evaluate weight gain at 3 months following insulin therapy initiation and to determine if it is due to fat or fat free tissue. Methods. Fifty-eight patients with T2DM and initiation of insulin therapy were evaluated. Body composition was assessed with InBody720 device (Biospace, Korea) before and 3 months after the initiation of insulin therapy. Results. The insulin therapy was initiated with basal insulin in 84.48% of the cases. The initial dose of insulin was 22.76±12.89 units/day and increased at 3 months to 30.81±18.49 units/day (p<0.001). The initial HbA1c was 9.86±2.02% and decreased to 7.58±1.19% (p<0.001). The body weight increased from 87.01±17.37 kg to 88.04±16.64 kg (p=0.026). The fat body mass and the percent of fat decreased with no statistical significance; the intracellular and extracellular body water increased significantly (intracellular: 26.30±5.96 vs. 27.26±6.16; extracellular: 16.61±3.63 vs. 17.03±3.84; p<0.001). Conclusion. During the first 3 months after initiation of insulin therapy a modest weight gain due to increase in the body water after restoration of the metabolic balance was observed.

Aim. Alpha-lipoic acid (ALA) is a potent naturally occurring antioxidant and in the\r\npast years several studies suggested the fact that ALA can have positive effects on glucose\r\nmetabolism. We intended to evaluate in an open-label, non-randomized study, in usual\r\nambulatory settings, the effect intravenous ALA infusion on fructosamine level, in patients\r\nwith type 2 diabetes and painful peripheral diabetic neuropathy.\r\nPatients and methods. 28 consecutive patients with type 2 diabetes and painful\r\nperipheral diabetic neuropathy, treated with 10 daily infusions of 600 mg ALA in 300 ml of\r\nnormal saline, were included in the study. Fructosamine was measured with a colorimetric\r\nmethod. For the analysis of the results we have used the non-parametric Wilcoxon Signed\r\nRanks test.\r\nResults. There were 15 women and the mean (? SD) age and duration of diabetes were\r\n59.39 (? 7.92) and 9.46 ? 6.19 yr respectively. Mean (?SD) HbA1c at enrolment was 7.77\r\n? 1.18 %. The mean (?SD) value of fructosamine decreased significantly from 568.14\r\n(?190.67) &#956;mol/L to 467.10 (?126.98) &#956;mol/L (p < 0.0001). The mean decrease between the\r\nfirst and second measurement was 17.8%, 101.03 (?132.17) &#956;mol/L in absolute term.\r\nConclusions. Decrease in fructosamine concentration can be described at least as a\r\n&#8220;positive side effect&#8221; of ALA used for the treatment of the painful peripheral diabetic neuropathy.\r\nAs far as we know there is only one study that used fructosamine as a criterion for evaluating the\r\nsafety and tolerability of orally administred ALA in patients with type 2 diabetes.